Abstracts

975 – Identifying Where HIV Self-Screening Has Greatest Impact: Analysis of Routine Data in South Africa

Background HIV self-screening (HIVSS) has the potential to close HIV testing gaps by allowing individuals to test themselves rapidly and privately and thus extend testing access to populations less likely to engage with health facilities. Quantifying the downstream effects of HIVSS, particularly uptake, facility-confirmed diagnoses, and linkage to care, however, remains a challenge when relying…

506 – Discontinuation of Dolutegravir Therapy Due to Any Drug-Related Event Among PLWH in Brazil

Background Since the Brazilian government introduced Dolutegravir (DTG)-as first-line therapy (2017), some observational studies reported discontinuation rates due to metabolic and central nervous system toxicities. There is a need to determine tolerability and identify adverse outcomes associated with increased use of Integrase inhibitors in low- and middle-income countries, where late presentation and coinfection with opportunistic infections…

531 – Twenty Months After Discontinuation of Cabotegravir/Rilpivirine: What Happens Next?

Background Data on cabotegravir and rilpivirine (CAB/RPV) use are increasing, but little is known about outcomes after treatment discontinuation (TD). Aims of the study were to characterize switch regimens, to estimate the probability of TD after CAB/RPV discontinuation and to assess changes in immunologic and metabolic parameters during CAB/RPV vs. subsequent oral antiretroviral therapy (ART).…

831 – Impact of Prenatal HIV and Congenital Cytomegalovirus on Neurodevelopment in Malawian Children

Background The prevalence of congenital cytomegalovirus (cCMV) and its long-term impact on HIV-exposed uninfected children remains poorly understood, and little data exist from sub-Saharan Africa, where the burden of both infections is greatest. We assessed whether prenatal HIV exposure increases the risk of cCMV and whether cCMV contributes independently or jointly with HIV to early…

866 – 20-Year Survival Outcomes of the First Pediatric HIV Cohort to Start Antiretroviral Therapy in Haiti

Background The GHESKIO HIV clinic in Haiti was among the first to provide antiretroviral therapy (ART) when it became available in 2003. Children with HIV have endured decades of ART and grown up managing numerous psychosocial challenges. As the first pediatric HIV cohorts enter young adulthood, understanding long-term survival is essential to evaluate program impact…

620 – Cancer Incidence and Risk Factors Among People With HIV in REPRIEVE

Background People with HIV (PWH) have an increased cancer risk compared to the general population. Cancer is a leading cause of morbidity and mortality among PWH. An enhanced understanding of cancer incidence and contributing risk factors, particularly among those well -treated on ART, may guide concomitant individual- and population-level preventive interventions. Methods Analyses were performed…